公开(公告)号：EP1541177A1

公开(公告)日：2005-06-15

申请号：EP03791200.3

申请日：2003-08-07

申请人： HISAMITSU PHARMACEUTICAL CO., INC.

发明人： TERAHARA, T. c/o HISAMITSU PHARMACEUTICAL CO., INC ,  AIDA, K., c/o HISAMITSU PHARMACEUTICAL CO., INC. ,  TOSHIMITSU, A. HISAMITSU PHARMACEUTICAL CO., INC. ,  HIGO, N. c/o HISAMITSU PHARMACEUTICAL CO., INC.

IPC分类号： A61K47/32 ,  A61K9/70 ,  A61K31/405 ,  A61K31/4422 ,  A61K31/48 ,  A61K47/06 ,  A61K47/12

CPC分类号： A61K9/7053 ,  A61K9/7061 ,  A61K9/7076 ,  A61K31/405 ,  A61K31/4422 ,  A61K31/48

摘要： A patch comprising a backing layer and an adhesive layer disposed on the backing layer and compounded with a drug and an adhesive base agent, wherein the adhesive base agent comprises styreneisoprene-styrene block copolymer, 2-ethylhexyl acrylate - vinyl acetate copolymer and a basic nitrogen-including polymer including a basic nitrogen and having no adhesion property at normal temperature.

摘要翻译： 1。一种贴剂，其包含背衬层和布置在所述背衬层上并与药物和粘合剂基剂复合的粘合剂层，其中所述粘合剂基剂包含苯乙烯 - 异戊二烯 - 苯乙烯嵌段共聚物，丙烯酸2-乙基己酯 - 乙酸乙烯酯共聚物和碱性氮 - 包括含有碱性氮的聚合物，并且在常温下不具有粘附性。

公开(公告)号：EP1512403A1

公开(公告)日：2005-03-09

申请号：EP04105405.7

申请日：2000-11-30

申请人： Polichem S.A.

发明人： Mailland, Federico

IPC分类号： A61K31/48 ,  A61K9/20

CPC分类号： A61K31/48 ,  A61K9/2018 ,  A61K9/2027 ,  A61K9/2031 ,  A61K9/2054

摘要： A method of improving bioavailability of ergot derivatives administered using sustained-release delivery systems includes combining an ergot derivative or mixture thereof with a pharmaceutically acceptable hydrophilic swelling agent or mixture thereof and one or more pharmaceutically acceptable excipients. The bioavailability of sustained-release formulations of the present invention is at least equal to the bioavailability of the ergot derivative or mixture thereof administered using a conventional delivery system. Sustained-release compositions that improve bioavailability are also provided. Methods and compositions according to the present invention may provide sustained-release characteristics while improving the bioavailability of ergot derivatives.

摘要翻译： 提高使用持续释放递送系统给药麦角衍生物的生物利用度的方法，包括组合麦角衍生物或混合物与药学上可接受的亲水性膨润剂或它们的混合物和一种或多种药学上可接受的赋形剂物。 本发明的缓释性制剂蒸发散的生物利用度至少等于使用常规递送系统其经管的麦角衍生物或混合物的生物利用度。持续释放组合物确实提高生物利用度，因此被提供。 方法和组合物gemäß到本发明而改进麦角衍生物的生物利用度可以提供持续释放特性。

公开(公告)号：EP1406568A4

公开(公告)日：2004-12-15

申请号：EP02749899

申请日：2002-07-10

申请人： CIMA LABS INC

发明人： PATHER S INDIRAN ,  HONTZ JOHN ,  SIEBERT JOHN M

IPC分类号： A61K9/02 ,  A61K9/20 ,  A61K9/22 ,  A61K31/437 ,  A61K31/4725 ,  A61K31/5415 ,  A61K47/02 ,  A61K47/04 ,  A61K47/12 ,  A61K47/26 ,  A61K47/36 ,  A61F13/02 ,  A61K9/52 ,  A61K31/48

CPC分类号： A61K9/0034 ,  A61K9/025 ,  A61K9/2054 ,  A61K9/2081 ,  A61K31/48

公开(公告)号：EP1428527A1

公开(公告)日：2004-06-16

申请号：EP04075596.9

申请日：1996-06-07

申请人： ALZA Corporation

发明人： Yum, Su II ,  Nelson, Melinda K. ,  Campbell, Patricia S.

IPC分类号： A61K9/70 ,  A61K31/48 ,  A61P25/16

CPC分类号： A61K9/7053 ,  A61K9/0014 ,  A61K9/7084 ,  A61K31/48 ,  A61K47/14 ,  A61K47/18 ,  Y10S514/947

摘要： Composition of matter for application to a body surface or membrane to administer pergolide by permeation through the body surface or membrane, the composition comprising pergolide to be administered, at a therapeutically effective rate, alone or in combination with a permeation enhancer or mixture. Also disclosed are drug delivery devices containing the pergolide or pergolide and enhancer composition and methods for the transdermal administration of the pergolide and pergolide/enhancer composition.

摘要翻译： 用于通过穿过身体表面或膜渗透的身体表面或膜施用培高利特的物质的组成，所述组合物包含单独或与渗透增强剂或混合物组合的待施用的百戈来替（治疗有效率）。 还公开了含有pergolide或pergolide和增强剂组合物的药物递送装置和透皮给药pergolide和pergolide /增强剂组合物的方法。

公开(公告)号：EP1389097A1

公开(公告)日：2004-02-18

申请号：EP02731896.3

申请日：2002-05-20

申请人： Alexza Molecular Delivery Corporation

发明人： RABINOWITZ, Joshua, D. ,  ZAFFARONI, Alejandro, C.

IPC分类号： A61K9/72 ,  A61K31/46 ,  A61K31/48 ,  A61K31/4045 ,  A61K31/13 ,  A61K31/137

CPC分类号： A61K9/007 ,  A61K9/0073 ,  A61K9/12 ,  A61K31/00 ,  A61K31/137 ,  A61K31/138 ,  A61K31/165 ,  A61K31/19 ,  A61K31/192 ,  A61K31/195 ,  A61K31/216 ,  A61K31/27 ,  A61K31/404 ,  A61K31/405 ,  A61K31/407 ,  A61K31/4196 ,  A61K31/421 ,  A61K31/422 ,  A61K31/423 ,  A61K31/437 ,  A61K31/473 ,  A61K31/485 ,  A61K31/49 ,  A61K31/495 ,  A61K31/496 ,  A61K31/4985 ,  A61K31/501 ,  A61K31/519 ,  A61K31/53 ,  A61K31/551 ,  A61K31/5517 ,  A61K47/54 ,  A61M11/042 ,  A61M15/06 ,  A61M2205/8206 ,  F24V30/00 ,  Y10S514/923 ,  Y10S514/958

摘要： The present invention relates to the delivery of sedative-hypnotics through an inhalation route. Specifically, it relates to aerosols containing sedative-hypnotics that are used in inhalation therapy. In a composition aspect of the present invention, the aerosol comprises particles comprising at least 5 percent by weight of a sedative-hypnotic. In a method aspect of the present invention, a sedative-hypnotic is delivered to a mammal through an inhalation route. The method comprises: a) heating a composition, wherein the composition comprises at least 5 percent by weight of a sedative-hypnotic, to form a vapor; and, b) allowing the vapor to cool, thereby forming a condensation aerosol comprising particles, which is inhaled by the mammal. In a kit aspect of the present invention, a kit for delivering a sedative-hypnotic through an inhalation route to a mammal is provided which comprises: a) a composition comprising at least 5 percent by weight of a sedative-hypnotic; and, b) a device that forms a sedative-hypnotic containing aerosol from the composition, for inhalation by the mammal.

公开(公告)号：EP1366762A1

公开(公告)日：2003-12-03

申请号：EP02702809.1

申请日：2002-03-07

申请人： HISAMITSU PHARMACEUTICAL CO., INC.

发明人： TATEISHI,T., Tsukuba Lab HISAMITSU PHARMA.CO, INC ,  TERAHARA,T., Tsukuba Lab HISAMITSU PHARMA. CO, INC ,  HIGO, N., Tsukuba Lab HISAMITSU PHARMA. CO, INC

IPC分类号： A61K9/70 ,  A61K47/32 ,  A61K31/48 ,  A61K31/216

CPC分类号： A61K9/7053 ,  A61K9/7061 ,  A61K9/7076 ,  A61K31/216 ,  A61K31/48 ,  A61K47/32

摘要： A patch agent of the present invention comprises a support, and an adhesive layer laid on the support and containing an adhesive base and a drug, wherein the adhesive base contains an acrylic polymer substantially having no carboxyl and no hydroxyl in molecules thereof, and a rubber-based polymer, so as to achieve sufficiently high skin permeability of the drug and preparation properties. Accordingly, the present invention enables administration of the drug through skin to be implemented with drug administration effect at a sufficiently high level and on a stable basis.

摘要翻译： 本发明的贴剂包括载体和铺设在载体上并含有粘合剂基料和药物的粘合剂层，其中所述粘合剂基底含有基本上不具有羧基并且其分子中不含羟基的丙烯酸聚合物，以及橡胶 的聚合物，以达到足够高的药物的皮肤渗透性和制备性能。 因此，本发明能够以足够高的水平和稳定的基础通过皮肤进行药物给药作用的施用。

公开(公告)号：EP1341530A1

公开(公告)日：2003-09-10

申请号：EP01969648.3

申请日：2001-08-24

申请人： Schering Aktiengesellschaft

发明人： KUHN, Karsten

IPC分类号： A61K9/70 ,  A61K31/48 ,  A61P25/16

CPC分类号： A61K9/7061 ,  A61K31/165 ,  A61K31/195 ,  A61K31/48 ,  A61K2300/00

摘要： The invention relates to the use of a dopamine agnostic active ingredient with a short half-life in the form of a transdermal therapeutic system (TTS) for treating illnesses which can be treated by dopaminergic means.

公开(公告)号：EP0735863B1

公开(公告)日：2002-11-13

申请号：EP95906146.6

申请日：1994-12-22

申请人： ERGO SCIENCE INCORPORATED ,  GENEVA PHARMACEUTICALS, INC.

发明人： CINCOTTA, Anthony N. ,  CINCOTTA, Manuel, Jr. ,  TIGNER, Susan Louise ,  RUNICE, Christopher Eric ,  PELLONI, Christopher Louis

IPC分类号： A61K9/20 ,  A61K31/44 ,  A61K31/495 ,  A61K31/48

CPC分类号： A61K31/4985 ,  A61K9/2013 ,  A61K31/00 ,  A61K31/475 ,  A61K31/48 ,  A61K45/06

摘要： Disclosed herein is a solid oral dosage form comprising bromocriptine and one or more pharmaceutically acceptable excipients. The oral dosage form has a dissolution rate in excess of 90 % in 5 minutes in 500 ml of 0.1N HCl aqueous medium at 37 °C and is useful for adjusting the plasma prolactin profile of a patient.

公开(公告)号：EP1235574A2

公开(公告)日：2002-09-04

申请号：EP00985142.9

申请日：2000-11-30

申请人： Polichem S.A.

发明人： MAILLAND, Federico

IPC分类号： A61K31/48 ,  A61K9/20

CPC分类号： A61K31/48 ,  A61K9/2018 ,  A61K9/2027 ,  A61K9/2031 ,  A61K9/2054

摘要： A method of improving bioavailability of ergot derivatives administered using sustained-release delivery systems includes combining an ergot derivative or mixture thereof with a pharmaceutically acceptable hydrophilic swelling agent or mixture thereof and one or more pharmaceutically acceptable excipients. The bioavailability of sustained-release formulations of the present invention is at least equal to the bioavailability of the ergot derivative or mixture thereof administered using a conventional delivery system. Sustained-release compositions that improve bioavailability are also provided. Methods and compositions according to the present invention may provide sustained-release characteristics while improving the bioavailability of ergot derivatives.

公开(公告)号：EP0957914A4

公开(公告)日：2002-07-24

申请号：EP97937297

申请日：1997-08-15

申请人： POZEN INC

发明人： PLACHETKA JOHN R

IPC分类号： A61K31/167 ,  A61K31/19 ,  A61K31/192 ,  A61K31/40 ,  A61K31/404 ,  A61K31/4045 ,  A61K31/405 ,  A61K31/48 ,  A61K31/495 ,  A61K45/06 ,  A61P25/06 ,  A61P43/00 ,  C07D209/16

CPC分类号： A61K31/48 ,  A61K31/19 ,  A61K31/40 ,  A61K31/405 ,  A61K31/495 ,  A61K45/06 ,  A61K2300/00

摘要： This invention comprises a method of treating migraine in a human comprising co-timely administering of a therapeutically effective amount of a 5-HT agonist coordinated with a therapeutically effective amount of an analgesic, particularly a long-acting NSAID, and in some instances, doses below those ordinarily considered as minimum effective doses as to one or both 5-HT agonist and long-acting NSAID. Dosage forms are also included herein.